Key Summary Points {#FPar1}
==================

***Why carry out this study?***Patients who take oral anticoagulants (OACs) and require emergency surgery or experience medical trauma may need rapid reversal of the anticoagulant effect to reduce bleeding risks.To assess the need for reversal agents, we determined the incidence of major surgeries or major bleeding associated with fractures and trauma using data from 62,888 OAC-naive Japanese patients with nonvalvular atrial fibrillation (NVAF) who initiated OACs***What was learned from this study?***The overall incidence rate (IR) of emergency surgery or major bleeding due to fracture or trauma was 0.489 per 100 patient-years.The IR in patients aged ≥ 75 years was almost double that in patients aged ≤ 64 years (0.611 and 0.317 per 100 patient-years, respectively).Although the IR was quite low, this study highlights the importance of having an effective reversal agent for patients on OACs, particularly older patients.

Introduction {#Sec1}
============

Nonvalvular atrial fibrillation (NVAF) is a major risk factor for thromboembolism and increased incidence of stroke in affected individuals \[[@CR1], [@CR2]\]. While the oral anticoagulant (OAC) warfarin, a vitamin K antagonist (VKA), prevents stroke in patients with NVAF \[[@CR1], [@CR3]\], it increases the risk of hemorrhage and adverse events due to its drug--drug interactions, food--drug interactions, and variable patient response via genetic polymorphisms \[[@CR4]--[@CR6]\]. Direct OACs (DOACs) have been developed to overcome these limitations \[[@CR7]\], and include dabigatran, rivaroxaban, apixaban, and edoxaban \[[@CR8]\]. Patients taking DOACs who undergo major emergency surgeries or experience medical trauma may require rapid reversal of the anticoagulant effect to reduce their risk of bleeding due to anticoagulation \[[@CR9]\]. For all reversal agents, the benefits of stopping or reducing bleeding must be balanced against the risk of thrombosis while anticoagulation is reversed \[[@CR10], [@CR11]\].

Given its aging population---about 27% of the population in Japan are aged ≥ 65 years \[[@CR12]\]---clinical scenarios requiring anticoagulant reversal are expected to be encountered more frequently in Japan, and this is for two main reasons. Firstly, around one-half of the patients experiencing severe trauma in Japan are aged \> 60 years (52.9% of 127,303 trauma patients), with the most frequent cause being ground-level falls (55.2%) \[[@CR13]\]. Emergency surgery for bone fractures was frequent among elderly trauma patients in a study in Japan (*n* = 631); it was reported in 25% of those aged 65--84 and in 18% of those aged ≥ 85 years \[[@CR14]\]. Secondly, anticoagulant usage (warfarin or DOACs) among 8855 adult patients with NVAF in Japan increased between 2006 and 2013 from 20.0 to 49.1%, with a more dramatic increase in the subgroup aged 65--74 years (7.9--59.9%) \[[@CR15]\]. Specific prescription data for DOACs in 2014 suggests that they comprise \~ 40% of all anticoagulant prescriptions in patients with NVAF (aged 18--74 years, *n* = 4380) \[[@CR16]\].

What is not yet known is the incidence rate of emergency surgery or bleeding related to trauma or fracture specifically among patients with NVAF taking DOACs in Japan. The aim of the present study was to assess the need for reversal agents in Japanese patients with NVAF on OAC therapy by determining the incidence of emergency surgeries and major bleeding episodes associated with fractures and trauma in this patient population.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

This retrospective, non-interventional study was based on data from existing health insurance claims in Japan. The Japanese Medical Data Vision (MDV) clinical database was used. The MDV database contains data from hospital information systems and administrative claims covering more than 12.94 million patients attending 280 acute hospitals as in- or out-patients within secondary medical care blocks in Japan. These hospitals used the Diagnosis Procedure Combination (DPC) case-mix classification system for inpatient reimbursement claims. Approximately 1500 hospitals are designated as DPC hospitals in Japan \[[@CR17]\]. The database contains anonymous information from health insurance claims for outpatients, DPC claims for inpatients, prescriptions, operations and medical procedures, hospitalization and results of laboratory tests from some of the participating hospitals \[[@CR18]\].

The study protocol was reviewed and approved by the Keio University's Faculty of Pharmacy Ethics Committee for Research involving humans, which also waived the informed consent requirements on October 11, 2017 in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects and the Declaration of Helsinki (1964) and its later amendments. The study was registered with ClinicalTrials.gov (NCT03254147).

OAC-naive adult patients with NVAF who initiated anticoagulant therapy with dabigatran, warfarin, apixaban, rivaroxaban, or edoxaban between March 14, 2011 and June 30, 2016 were included in the study. The main inclusion criteria were: patients (age \> 18 years) with confirmed diagnosis of NVAF (International Classification of Diseases \[ICD\] 10 I48), having a first prescription (index date) of any one of the OACs (dabigatran, warfarin, rivaroxaban, apixaban, or edoxaban), and having no prescription of OACs for 6 months prior to the index date (baseline period), as well as enrolment in the MDV database for at least 6 months. The main exclusion criteria were: patients on OAC therapy and patients who underwent dialysis or kidney transplant during the baseline period; patients with atrial flutter, valvular atrial fibrillation (AF), mechanical valve placement, rheumatic AF, and/or mitral valve prolapse/regurgitation/stenosis during the baseline period; patients with a record of deep vein thrombosis or pulmonary embolism within 6 months of AF diagnosis during the baseline period; and patients receiving treatment with two or more OACs at index date.

To calculate the incidence rate of clinical events during OAC treatment, treatment duration was expressed in patient-years of follow-up. The follow-up period was defined from the day after the index date to the date of any OAC treatment discontinuation, end of continuous enrolment in the database, end of the study period, first occurrence of an event of interest, or death, whichever came earlier. On OAC observation time after switching from one OAC to another was included in the primary analysis, and a sensitivity analysis was undertaken that censored for events after the switch.

Patients were stratified on the basis of prescribed OAC and age (≤ 64 years, 65--74 years and ≥ 75 years).

Outcomes {#Sec4}
--------

The primary objective of the study was to assess the overall and age-stratified incidence rates of emergency surgery and major bleeding due to fracture and trauma in adult patients initiating OAC therapy for NVAF. Emergency surgery was defined as any surgical procedure (ICD10 code K000-879) performed on the day of hospital admission with additional claims associated with urgent fee MDV codes (114701370, 160000210, 180709110). Major bleeding due to fracture was defined as any bleeding associated with hospitalization or blood transfusion (ICD10 code K920) in patients with fracture (ICD 10 codes M484, M80, S021, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02, T08, T10, T12, T142) listed as the primary diagnosis (i.e., the diagnosis requiring the most medical resource). Major bleeding due to trauma was defined as any bleeding associated with hospitalization or blood transfusion (ICD10 code K920) in patients with any kind of trauma (ICD 10 codes S00-S09, I620, M125, M164, M165, M172, M173, M191, M483, M872, S065, S066, S081, S089, S130, S18, S230, S480, S481, S532, S533, S580, S581, S589, S633, S634, S680, S681, S684, S688, S689, S780, S789, S889, S980, S981, S982, T050, T053, T058, T059, T116, T136, T147, T794, T796, T797, S271, S272, S330, S334, S382), listed as the primary diagnosis.

The secondary objective of the study was to assess the overall and age-stratified incidence rates of cardiac tamponade and pericardiocentesis. All cardiac tamponade (ICD 10 code 4200001) and pericardiocentesis cases (MDV procedure code 140010510) on the same or next day as catheter ablation or percutaneous coronary intervention (MDV procedure codes 150153910, 150267810, 150263310, 150284310, 150303310, 150345710, 150374910, 150375010, 150375210, 150375310, 150375410) were included. The types of emergency surgeries were also identified in the study population.

Statistical Analysis {#Sec5}
--------------------

All MDV data used during the study were in electronic format and were managed by Milliman Inc. Statistical analysis was performed using SAS version 9.4 and Microsoft Excel 2010. Descriptive statistical methods were used for analyzing baseline and outcomes data. The primary outcomes, further outcomes and patient characteristics were determined both in total and in age-stratified groups.

Results {#Sec6}
=======

Within the database, 62,888 patients with NVAF who initiated OAC monotherapy were identified, of whom 53,969 met the criteria for study inclusion (Fig. [1](#Fig1){ref-type="fig"}). Overall, 40% of the study population were female and 60% of the overall cohort were aged ≥ 75 years. The mean age ± SD of the study cohort was 76 ± 10 years (Table [1](#Tab1){ref-type="table"}).Fig. 1Patient flow diagram. *AF* atrial fibrillation, *OAC* oral anticoagulants. \*Between March 14, 2011 and June 30, 2016Table 1Baseline patient characteristicsNVAF patients (*n* = 53,969)Females, *n* (%)21,587 (40.0)Mean ± SD age, years76 ± 10Age categories, *n* (%) ≤ 64 years6960 (12.9) 65--74 years14,568 (27.0) ≥ 75 years32,441 (60.1)Comorbidities, % Arterial hypertension56 Heart failure33 Bleeding29 Diabetes mellitus24 Dyslipidemia22 Valvular disease22 Stroke or transient ischemic attack11 Peripheral artery disease8 Liver disease8 Fracture5 Dementia3 Myocardial infarction2 Kidney impairment2 Trauma2 Nursing home resident1Concomitant medication, *n* (%) Calcium channel blockers23,474 (43.5) Proton pump inhibitor21,647 (40.1) β-blocker19,044 (35.3) Diuretics18,966 (35.1) ARB/ACEI17,838 (33.1) Statins11,083 (20.5) Aspirin10,313 (19.1) H~2~ receptor antagonist8630 (16.0) Clopidogrel4261 (8.0) Amiodarone1209 (2.2)*ACEI* angiotensin-converting enzyme inhibitors, *ARB* angiotensin receptor blockers, *SD* standard deviation

Primary Outcome {#Sec7}
---------------

When the follow-up time after switching OAC was included, a total of 27,190 patient-years of follow-up were evaluated in the present study. During follow-up, 133 events of emergency surgery or major bleeding due to fracture or trauma were reported, with the incidence rate calculated as 0.489 per 100 patient-years (95% confidence interval \[CI\] 0.406--0.572). When the follow-up time after switching OAC was excluded, the corresponding figures were 22,972 patient-years and 111 events, with a similar overall incidence rate (0.483 per 100 patient-years, 95% CI 0.394--0.573) (Table [2](#Tab2){ref-type="table"}).Table 2Emergency surgery and major bleeding due to fracture or trauma ≤ 64 years\
(*n* = 6960)65--74 years (*n* = 14,568) ≥ 75 years\
(*n* = 32,441)Total\
(*n* = 53,969)Including time after oral anticoagulant switching Follow-up, patient-years4412902813,75027,190 Patients with any event, *n*143584133 IR per 100 patient-years (95% CI)0.317 (0.151, 0.483)0.388 (0.259, 0.516)0.611 (0.481, 0.741)0.489 (0.406, 0.572)Excluding time after oral anticoagulant switching Follow-up, patient-years3700758411,68822,972 Patients with any event, *n*122871111 IR per 100 patient-years (95% CI)0.324 (0.141, 0.508)0.369 (0.233, 0.506)0.607 (0.467, 0.748)0.483 (0.394, 0.573)*CI* confidence interval, *IR* incidence rate

The incidence rates of emergency surgery events or major bleeding events due to fracture or trauma in the subgroup aged ≥ 75 years (0.611 per 100 patient-years) were almost double those aged 65--74 years or ≤ 64 years (0.388 and 0.317 per 100 patient-years, respectively) in the analysis that included follow-up after switching OAC. Similar results were noted in the analysis that excluded any follow-up time after switching OAC treatment (Table [2](#Tab2){ref-type="table"}). However, there was some overlap between age groups in the associated 95% CIs.

Secondary Outcome {#Sec8}
-----------------

One patient who received warfarin experienced cardiac tamponade and/or pericardiocentesis. Because of the low number of patients who experienced this outcome, the incidence rate was not calculated.

Discussion {#Sec9}
==========

We have determined that the annual incidence rate of emergency surgery or major hemorrhage associated with fracture and injury was \~ 0.5% among 53,969 adult NVAF patients on OAC therapy. In the subgroup of very elderly patients (aged ≥ 75 years) this annual rate was \~ 0.6%, which was almost double that of those aged ≤ 64 years (\~ 0.3%).

Since our study did not include assessment of OAC-related bleeding, only bleeding related to fractures or trauma/injury and emergency surgery, this may explain why our incidence rates were lower than reported in previous retrospective or observational analyses conducted in adult patients with NVAF receiving OAC therapy (warfarin or DOAC) that reported major bleeding incidence rates (2.4--7.5 per 100 person years \[[@CR19]--[@CR21]\]) or cumulative incidence (1.2--4.7% \[[@CR22], [@CR23]\]).

In addition, OAC-related major bleeding rates may generally be lower among Japanese patients than in patients from other countries, as exemplified by the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) ongoing multi-national observational study of stroke prevention in patients with newly diagnosed NVAF \[[@CR24]\]. In this study, the major bleeding event rate in Japan was 0.32 (95% CI 0.19--0.53) per 100 patient-years versus 0.91 (0.82--1.00) per 100 patient-years in other countries \[[@CR24]\]. Major bleeding incidence rates in one Japanese study were 2.2 per 100 patient-years (patients aged ≥ 75 years) and 1.4 per 100 patient-years (patients aged \< 75 years) among 9578 NVAF patients receiving rivaroxaban \[[@CR25]\]. Major bleeding rates associated with DOAC therapy (*n* = 1676) that varied by age were also reported by Nishida and colleagues \[[@CR26]\]: 0.973 per 100 patient-years (age \< 75 years), 1.720 per 100 patient-years (age 75--84 years), and 0.985 per 100 patient-years (≥ 85 years). Annualized major bleeding incidence rates in Japanese NVAF patients on warfarin were 1.2% per year and on a DOAC were 0.5% per year in an analysis of 3-year clinical outcomes of a Japanese registry study \[[@CR27]\]. Another Japanese claims database study reported the incidence rates per 1000 patient-years of major bleeding (6.39), GI bleeding (1.59), and intracranial bleeding (0) among 4606 dabigatran recipients \[[@CR28]\].

We did not determine the incidence rate of bleeding associated with fractures or trauma separately from emergency surgery. Falls are the primary cause of severe trauma in the elderly \[[@CR13]\]. Falls may lead to traumatic brain injury (TBI \[[@CR29]\]), traumatic spinal cord injury (TSCI \[[@CR30]\]), or fractures. The incidence of falls is higher with increasing age, as is the incidence of fractures. Several Japanese studies have reported an age-related increase in the incidence of ground-level falls resulting in severe trauma \[[@CR13]\], annual hip fracture incidence \[[@CR31]\], bone fractures requiring emergency surgery in trauma patients \[[@CR14]\], annual TSCI incidence \[[@CR30]\], and TBI from non-motor vehicle accident causes \[[@CR32]\]. While much of these data on falls, fractures, and severe traumatic injury are not specific for patients with NVAF receiving OAC therapy, the age-related increased incidence of such events makes it likely that trauma clinicians and surgeons will encounter patients with NVAF receiving OAC therapy.

Our study has defined the incidence rate of patients undergoing emergency surgery or who have bleeding associated with fractures or trauma in Japan. Together with data indicating that falls are a large contributory factor to the incidence of trauma in Japan \[[@CR13]\], that OAC-related bleeding may occur in up to 2.2% of patients with NVAF, and Japan's aging population, there is a clear reason to anticipate an increased need for anti-coagulation reversal agents.

The main limitation of the present study was the fact that, as a retrospective database analysis, it relied on the integrity of the source information. However, the definitions of outcomes used as endpoints would likely prevent any incorrectly coded events from being included in the analysis, so if anything, is likely to underestimate the incidence of events. Also, given its retrospective nature, it was not possible to capture information about the magnitude of change in hemoglobin levels or the severity of bleeding. As previously mentioned, the current analysis of outcomes was limited to hospitalized or transfused bleeding associated with fracture or trauma, and did not include life-threatening intracranial or GI bleeding, which were both indications for idarucizumab use in the RE-VERSE AD study \[[@CR33]\], or other OAC-related major bleeding. Therefore, this analysis probably underestimates the incidence of bleeding events that may require rapid reversal. Furthermore, the definition of emergency surgery used in the RE-VERSE AD study could not be replicated in this study since the database lacked hourly time stamp information. As a consequence, we used the definition of same day or 1 day after hospitalization, which could result in over-estimation of the incidence rates. Another limitation was that only Japanese patients were included, which could limit the applicability of the findings in other populations. Lastly, we did not conduct any analyses comparing outcomes in patients receiving different types of OACs (warfarin or individual DOACs) or in patients who received reversal agents such as FFP or vitamin K. Since prescribing decisions in real-world clinical practice are individualized for each patient, based on patient demographics and comorbidities, such analyses would be subject to selection and channeling bias that would be difficult to control for statistically, undermining the possibility of obtaining meaningful comparative data.

Conclusions {#Sec10}
===========

In conclusion, although relatively few patients with NVAF receiving OACs experience emergency surgeries and major bleeding episodes associated with fractures and trauma, the incidence rate of these events is markedly higher in patients of advanced age. This study highlights the importance of having an effective reversal agent for patients on OACs, particularly those in older age groups.
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